Literature DB >> 25216566

Prophylactic administration of Amifostine protects vessel thickness in the setting of irradiated bone.

Erin E Page1, Sagar S Deshpande2, Noah S Nelson2, Peter A Felice2, Alexis Donneys2, Jose J Rodriguez2, Samir S Deshpande2, Steven R Buchman2.   

Abstract

Although often beneficial in the treatment of head and neck cancer (HNC), radiation therapy (XRT) leads to the depletion of vascular supply and eventually decreased perfusion of the tissue. Specifically, previous studies have demonstrated the depletion of vessel volume fraction (VVF) and vessel thickness (VT) associated with XRT. Amifostine (AMF) provides protection from the detrimental effects of radiation damage, allowing for reliable post-irradiation fracture healing in the murine mandible. The purpose of this study is to investigate the prophylactic ability of AMF to protect the vascular network in an irradiated field. Sprague-Dawley rats (n = 17) were divided into 3 groups: control (C, n = 5), radiated (XRT, n = 7), and radiated mandibles treated with Amifostine (AMF XRT, n = 5). Both groups receiving radiation underwent a previously established, human equivalent dose of XRT totaling 35 Gy, equally fractionated over 5 days. The AMF XRT group received a weight dependent (0.5 mg AMF/5 g body weight) subcutaneous injection of AMF 45 min prior to XRT. Following a 56-day recovery period, mandibles were perfused, dissected, and imaged with μCT. ANOVA was used for comparisons between groups and p < 0.05 was considered statistically significant. Stereologic analysis demonstrated a significant and quantifiable restoration of VT in AMF treated mandibles as compared to those treated with radiation alone (0.061 ± 0.011 mm versus 0.042 ± 0.004 mm, p = 0.027). Interestingly, further analysis demonstrated no significant difference in VT between control mandibles and those treated with AMF (0.067 ± 0.016 mm versus 0.061 ± 0.011 mm, p = 0.633). AMF treatment also showed an increase in VVF, however those results were not statistically significant from VVF values demonstrated by the XRT group. Our data support the contention that AMF therapy acts prophylactically to protect vessel thickness. Based on these findings, we support the continued investigation of this treatment paradigm in its potential translation for the prevention of vascular depletion after radiotherapy.
Copyright © 2014 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amifostine; Mandible; Osteoradionecrosis; Prophylaxis; Radiotherapy; Vasularity

Mesh:

Substances:

Year:  2014        PMID: 25216566      PMCID: PMC4276456          DOI: 10.1016/j.bjps.2014.08.054

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  23 in total

1.  Long-term effects of radiation on the vascularity of rat bone--quantitative measurements with a new technique.

Authors:  D E Cutright; J M Brady
Journal:  Radiat Res       Date:  1971-11       Impact factor: 2.841

2.  Unique rodent model of distraction osteogenesis of the mandible.

Authors:  Steven R Buchman; Michael A Ignelzi; Caius Radu; Jonathan Wilensky; Andrew H Rosenthal; Lawrence Tong; Samuel T Rhee; Steven A Goldstein
Journal:  Ann Plast Surg       Date:  2002-11       Impact factor: 1.539

3.  Dose response of amifostine in protection of growth plate function from irradiation effects.

Authors:  T A Damron; J A Spadaro; B Margulies; L A Damron
Journal:  Int J Cancer       Date:  2000-04-20       Impact factor: 7.396

4.  Amifostine before fractionated irradiation protects bone growth in rats better than fractionation alone.

Authors:  T A Damron; B Margulies; D Biskup; J A Spadaro
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-06-01       Impact factor: 7.038

5.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.

Authors:  D M Brizel; T H Wasserman; M Henke; V Strnad; V Rudat; A Monnier; F Eschwege; J Zhang; L Russell; W Oster; R Sauer
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

6.  Inhibition of spontaneous metastases formation by amifostine.

Authors:  David J Grdina; Yasushi Kataoka; Jeffrey S Murley; Nancy Hunter; Ralph R Weichselbaum; Luka Milas
Journal:  Int J Cancer       Date:  2002-01-10       Impact factor: 7.396

7.  Amifostine inhibits angiogenesis in vivo.

Authors:  Efstathia Giannopoulou; Panagiotis Katsoris; Dimitris Kardamakis; Evangelia Papadimitriou
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

8.  Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice.

Authors:  David J Grdina; Yasushi Kataoka; Jeffrey S Murley; Kirsten Swedberg; John Y Lee; Nancy Hunter; Ralph R Weichselbaum; Luka Milas
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  Amifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells.

Authors:  Efstathia Giannopoulou; Evangelia Papadimitriou
Journal:  Free Radic Res       Date:  2003-11

Review 10.  Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.

Authors:  Christian Nicolaj Andreassen; Cai Grau; Jacob Christian Lindegaard
Journal:  Semin Radiat Oncol       Date:  2003-01       Impact factor: 5.934

View more
  5 in total

1.  Clinical Use of Deferoxamine in Distraction Osteogenesis of Irradiated Bone.

Authors:  Arash Momeni; Scott Rapp; Alexis Donneys; Steven R Buchman; Derrick C Wan
Journal:  J Craniofac Surg       Date:  2016-06       Impact factor: 1.046

2.  Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.

Authors:  Kavitha Ranganathan; Eric Simon; Jeremy Lynn; Alicia Snider; Yu Zhang; Noah Nelson; Alexis Donneys; Jose Rodriguez; Lauren Buchman; Dawn Reyna; Elke Lipka; Steven R Buchman
Journal:  Pharm Res       Date:  2018-03-19       Impact factor: 4.200

3.  Amifostine Suppresses the Side Effects of Radiation on BMSCs by Promoting Cell Proliferation and Reducing ROS Production.

Authors:  Bo Huang; Tao He; Qianqian Yao; Liang Zhang; Yang Yao; Hua Tang; Ping Gong
Journal:  Stem Cells Int       Date:  2019-01-09       Impact factor: 5.443

4.  Radioprotective Effect of Aminothiol PrC-210 on Irradiated Inner Ear of Guinea Pig.

Authors:  Arnaud P J Giese; Jess G Guarnaschelli; Jonette A Ward; Daniel I Choo; Saima Riazuddin; Zubair M Ahmed
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

5.  Overcoming Nuclear Winter: The Cutting-edge Science of Bone Healing and Regeneration in Irradiated Fields.

Authors:  Melissa Daniel; Alexandra O Luby; Lauren Buchman; Steven R Buchman
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.